17-AAG (tanespimycin) alleviates disease manifestations in SLE mouse models by reducing inflammation and immune cell activation
These conditions include aging and age-associated chronic muscle conditions such as cachexia 248 , sarcopenia 124,249,250 , inclusion body myositis (IBM) 114,251,252 , and neuromuscular diseases like Duchennes muscular dystrophy (DMD) 253,254
Five reviewers evaluated the paper, a Frontiers spokesperson clarified in a statement to The Transmitter , which reflects the collaborative and iterative nature of Frontiers peer-review process. Leisman did not provide additional information about the interventions performed in the program
We're a small business and pride ourselves in quality products and support!
Table of Contents: Do I need a specific BMI to qualify for GLP-1 weight loss treatments
: ( )